Therapeutic Options for Men with Castrate-Resistant Prostate Cancer

REVIEW ARTICLE

Reid V Graves, Nicholas A Laryngakis, S. Bruce Malkowicz and Thomas J Guzzo

Affiliation: Division of Urology, Department of Surgery, The Hospital of the University of Pennsylvania, Philadelphia, PA, USA

ABSTRACT

Prostate cancer (PCa) is the most common malignancy diagnosed in American men. Men with the clinically localized disease typically have an excellent prognosis; however, the overall survival of those with castrate-resistant metastatic prostate cancer is poor. Until recently, therapeutic options for men with castrate-resistant prostate cancer (CRPC) were limited. Further understanding of the complex molecular biology of the androgen receptor (AR) has led to the development of novel therapeutic strategies for men with CRPC. This article reviews both the current state of CRPC therapy and the potential future therapeutic struggles.


Keywords: prostate cancer, castrate-resistant prostate cancer

Correspondence: Thomas J Guzzo, Assistant Professor of Urology, Division of Urology, Department of Surgery, The Hospital of the University of Pennsylvania, Philadelphia, PA 19106, USA. Tel: +1-215-662-7018; Fax: +215-662-3955; email: thomas.guzzo@uphs.upenn.edu